Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial

Biology of Blood and Marrow Transplantation

Volumn 22, Issue 2, 2016, Pages 385-390

  Craddock, Charles ^a,b   Jilani, Nadira ^a,b   Siddique, Shamyla ^a,b   Yap, Christina ^a,b   Khan, Josephine ^b   Nagra, Sandeep ^a   Ward, Janice ^a   Ferguson, Paul ^a,b   Hazlewood, Peter ^a,b   Buka, Richard ^a   Vyas, Paresh ^c   Goodyear, Oliver ^b   Tholouli, Eleni ^d   Crawley, Charles ^e   Russell, Nigel ^f   Byrne, Jenny ^f   Malladi, Ram ^a,b   Snowden, John ^g   Dennis, Mike ^h  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

^h CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Acute myeloid leukemia; Azacitidine; Relapse; Tumor antigens

Indexed keywords

ALEMTUZUMAB; AMSACRINE; AZACITIDINE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; MELPHALAN; TUMOR ANTIGEN; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APNEA; ARTICLE; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EDEMA; FAINTNESS; FEMALE; FEVER; FLU LIKE SYNDROME; GRAFT VERSUS HOST REACTION; HEADACHE; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; INFECTION; INJECTION SITE REACTION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRURITUS; RASH; RECURRENCE FREE SURVIVAL; SKIN ABRASION; SKIN BRUISING; THROMBOCYTOPENIA; VOMITING; ALLOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; PROCEDURES; RECURRENT DISEASE; TRANSPLANTATION CONDITIONING;

ADULT; AGED; ALLOGRAFTS; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84958682804     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.09.004     Document Type: Article

References (29)

1. Cornelissen J.J., Gratwohl A., Schlenk R.F., et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012, 9:579-590.
2. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006, 24:444-453.
3. Appelbaum F.R. Hematopoietic-cell transplantation at 50. N Engl J Med 2007, 357:1472-1475.
4. Tauro S., Craddock C., Peggs K., et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005, 23:9387-9393.
5. Appelbaum F.R. Optimising the conditioning regimen for acute myeloid leukaemia. Best Pract Res Clin Haematol 2009, 22:543-550.
6. Craddock C., Nagra S., Peniket A., et al. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2010, 95:989-995.
7. Kroger N., Bacher U., Bader P., et al. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant 2010, 16:1187-1211.
8. Rettinger E., Willasch A.M., Kreyenberg H., et al. Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood 2011, 118:5681-5688.
9. Olavarria E., Siddique S., Griffiths M.J., et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007, 110:4614-4617.
10. Jabbour E., Giralt S., Kantarjian H., et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 2009, 115:1899-1905.
11. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010, 116:5420-5431.
12. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
13. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
14. Czibere A., Bruns I., Kroger N., et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 2010, 45:872-876.
15. Sockel K., Wermke M., Radke J., et al. Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse. Haematologica 2011, 96:1568-1570.
16. Goodyear O., Agathanggelou A., Novitzky-Basso I., et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010, 116:1908-1918.
17. Goodyear O.C., Dennis M., Jilani N.Y., et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 2012, 119:3361-3369.
18. Hambach L., Ling K.W., Pool J., et al. Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. Blood 2009, 113:2715-2722.
19. Choi J., Ritchey J., Prior J.L., et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010, 116:129-139.
20. Sanchez-Abarca L.I., Gutierrez-Cosio S., Santamaria C., et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood 2010, 115:107-121.
21. Schroeder T., Frobel J., Cadeddu R.P., et al. Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation. Leukemia 2013, 27:1910-1913.
22. Mohty M., Chevallier P. Azacitidine after allo-SCT: the good without the bad?. Blood 2012, 119:3199-3200.
23. Schmid C., Schleuning M., Ledderose G., et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005, 23:5675-5687.
24. Wehler T.C., Karg M., Distler E., et al. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. J Immunol Methods 2008, 339:23-37.
25. Wolfl M., Kuball J., Ho W.Y., et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007, 110:201-210.
26. Rezvani K., Yong A.S., Mielke S., et al. Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunol Immunother 2012, 61:1125-1136.
27. Schroeder T., Czibere A., Platzbecker U., et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013, 27:1229-1235.
28. Potter V.T., Krishnamurthy P., Barber L.D., et al. Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome. Biol Blood Marrow Transplant 2014, 20:111-117.
29. Shaw B.E., Apperley J.F., Russell N.H., et al. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. Br J Haematol 2011, 153:244-252.